GlassScriptPhysician profile
Cindy Hutson
NPI 1114941804
$7,194.99
in general payments reported to CMS, 2019-2025
26 companies · $1,451 in 2025
The $1,451 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $1,090 · 2021: $1,078 · 2022: $923 · 2023: $1,170 · 2024: $1,104 · 2025: $1,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,725.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,258.17 | 2021-2025 | |
| Glaxosmithkline, LLC. | $822.73 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $698.00 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $683.55 | 2020-2023 | Trintellix |
| Axsome Therapeutics, INC. | $622.98 | 2022-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $598.36 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Arbor Pharmaceuticals, INC. | $594.38 | 2019-2022 | |
| Lilly USA, LLC | $432.66 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $347.63 | 2019-2021 | |
| Novo Nordisk INC | $250.23 | 2020-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.56 | 2020-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $131.86 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $108.64 | 2023-2024 | Quviviq |
| Astellas Pharma US INC | $86.59 | 2019-2022 | |
| Allergan, INC. | $78.25 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $51.88 | 2025 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $42.35 | 2022 | |
| Amgen INC. | $34.41 | 2020 | |
| Exact Sciences Corporation | $29.30 | 2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $28.85 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $22.27 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $22.13 | 2024 | |
| Novartis Pharmaceuticals Corporation | $19.22 | 2022 | |
| Aytu Biopharma, INC. | $18.24 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.77 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Hutson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.